BIVI
BioVie Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.03
−0.25%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$17.11M
MomentumView details →
1D Return
−0.25%
YTD Return
+75.86%
RSI (14)
55.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$17.11M
RSI (14)
55.9
MomentumView details →
1D Return
−0.25%
YTD Return
+75.86%
SummaryUpdated Jun 1, 2026
BioVie Inc. (NASDAQ:BIVI) is a clinical-stage biotechnology company founded in 2013 and based in Carson City, Nevada. Originally incorporated as NanoAntibiotics, Inc., the company rebranded to BioVie Inc. in July 2016 and went public in September 2020. BioVie focuses on discovering, developing, and commercializing novel drug therapies, with a particular emphasis on treatments for neurological disorders and liver diseases. The company operates as a pure-play research and development organization with no current revenue-generating products, as all of its therapeutic candidates remain in various stages of clinical trials.
Similar companies
Latest newsMore news →
BioVie Inc. completed the treatment phase of its ADDRESS-LC Phase 2 trial of bezisterim for neurological symptoms of Long COVID.4d agoBioVie announced topline results from its Phase 2 SUNRISE-PD trial of bezisterim in early Parkinson's disease, showing statistically significant improvements versus placebo on motor and non-motor symptoms.29d ago